Hims & Hers Health Trading 22% Higher, WIth Gains Attributed to FDA Nominee
Hims & Hers Health Trading 22% Higher, WIth Gains Attributed to FDA Nominee
Hims & Hers shares have surged over 200% this year, putting the company on track for its best annual performance since going public.$Hims & Hers Health (HIMS.US)$ shares are trading 22% higher on Monday afternoon. Its strength has been attributed to President-elect Donald Trump's plans to nominate Marty Makary to lead the FDA.
$Hims & Hers Health (HIMS.US)$ 截至星期一下午，股票交易上漲了22%。這種強勁表現歸因於當選總統特朗普計劃提名馬蒂·馬卡里擔任FDA的領導。
Bloomberg reported earlier that a Hunterbrook Media report shared the connection of Makary and Hims & Hers: Makary is an executive at Sesame Inc., a startup that also offers compounded GLP-1 weight loss drugs.
彭博社早些時候報道稱，Hunterbrook Media的報告分享了馬卡里與Hims & hers的聯繫：馬卡里是Sesame Inc.的高管，該初創公司還提供複合GLP-1減肥藥概念。
Hunterbrook Capital, the hedge fund behind the report, revealed it is now holding long positions in Hims shares, reversing its June short bet, which had focused on the company’s online sales of compounded GLP-1 injections.
報告背後的對沖基金Hunterbrook Capital透露，它現在持有Hims股票的多頭頭寸，逆轉了6月時專注於該公司在線銷售複合GLP-1注射劑的空頭押注。
Hims & Hers shares have surged over 200% this year, putting the company on track for its best annual performance since going public.
Hims & hers的股票今年暴漲超過200%，使公司有望實現自上市以來最佳年度業績。
However, Wall Street remains cautious, with more than half of analysts covering the stock issuing hold or sell ratings, according to Bloomberg data. Nearly 40% of analysts have a buy recommendation for the shares.
然而，華爾街依然保持謹慎，超過一半的分析師對該股給予持有或賣出的評級，彭博社數據顯示，近40%的分析師對該股票發出了買入推薦。
